Abstract: Antiphospholipid antibody (APL) is associated with the adverse events of pregnancy closely, such as recurrent abortion, intrauterine growth restriction, preeclampsia, fetal death and premature delivery. Some scholars believe that APL is one of the reasons for the failure of in vitro fertilization and embryo transfer (IVF-ET). The failure rate of IVF and the pregnancy complications in APL-positive patients were higher than those in APL-negative patients. The frequency of IVF failure could be increased in those patients with persistent- or triple-positive APL. Up to now, there is still no consensus on the antibody testing, and prevention and management, in the APL-positive patients undergoing IVF-ET treatment. Some scholars suggest that patients undergoing IVF-ET treatment should be screened for APL, and that APL-positive patients should be treated with prophylactic anticoagulant or low-dose of aspirin (75-100 mg/d) to prevent thrombosis and to improve the clinical outcomes. However, some studies showed that the relationship between APL and IVF outcomes still lacks the support from the evidence-based medicine, and that APL screening and preventive treatment be not recommended for IVF-ET patients. In this article, we review the research progress on the diagnosis and treatment strategies of APL-positive patients undergoing IVF-ET.

Key words: Antibodies, antiphospholipid；, Beta 2-glycoprotein Ⅰ；, Antiphospholipid syndrome；, Fertilization in vitro；, Embryo transfer；, Reproductive techniques, assisted